View Older Stories View More Recent Stories

May 20, 2022 07:30AM BridgeBio Pharma's (BBIO) Phoenix Tissue Repair Reports Positive Results from Phase 2 Trial of PTR-01
May 20, 2022 07:30AM BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 20, 2022 07:30AM BridgeBio Pharma Affiliate Phoenix Tissue Repair Announces Positive Results from Phase 2 Trial of PTR-01, a Protein Replacement Therapy for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
May 17, 2022 07:30AM BridgeBio Pharma to Participate in May Investor Events
May 17, 2022 07:30AM BridgeBio Pharma to Participate in May Investor Events
May 13, 2022 07:30AM BridgeBio Pharma Inc. (BBIO) Sells Rare Pediatric Disease Priority Review Voucher for $110M, Defers Principal Payment on Senior Debt by Two Years
May 13, 2022 07:30AM BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
May 13, 2022 07:30AM BridgeBio Pharma Sells Rare Pediatric Disease Priority Review Voucher for $110 Million and Defers Principal Payment on Senior Debt by Two Years
May 12, 2022 07:31AM BridgeBio Pharma Inc. (BBIO) Enters Exclusive License Agreement with Bristol Myers Squibb (BMY) to Develop and Commercialize BBP-398
May 12, 2022 07:30AM BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
May 12, 2022 07:30AM BridgeBio Announces Exclusive License Agreement with Bristol Myers Squibb to Develop and Commercialize BBP-398, a Potentially Best-in-Class SHP2 Inhibitor, in Oncology
May 10, 2022 04:30PM BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference
May 10, 2022 04:30PM BridgeBio Pharma to Participate in the Bank of America Securities Healthcare Conference
May 5, 2022 07:32AM BridgeBio Pharma Inc. (BBIO) Reports Q1, Provides Business Update
May 5, 2022 07:30AM BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
May 5, 2022 07:30AM BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update
Apr 4, 2022 05:54AM BridgeBio Pharma Inc. (BBIO) Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in ATTR-CM
Apr 3, 2022 08:36AM BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Apr 3, 2022 08:36AM BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Mar 28, 2022 07:30AM BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual S
Mar 28, 2022 07:30AM BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual S
Mar 14, 2022 07:30AM BridgeBio Pharma Inc. (BBIO) Reports Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Mar 14, 2022 07:30AM BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Mar 14, 2022 07:30AM BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Mar 11, 2022 07:30AM BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Mar 11, 2022 07:30AM BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)
Mar 8, 2022 07:30AM BridgeBio Pharma Inc. (BBIO) Announces Asset Purchase Agreement with Sentynl for BridgeBio Pharma’s NULIBRY (Fosdenopterin)
Mar 8, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)
Mar 8, 2022 07:30AM BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma’s NULIBRY™ (Fosdenopterin)
Mar 3, 2022 07:32AM BridgeBio Pharma Inc. (BBIO) and Helsinn Group Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
Mar 3, 2022 07:30AM Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
Feb 24, 2022 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
Feb 24, 2022 07:30AM BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
Jan 27, 2022 07:30AM BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
Jan 27, 2022 07:30AM BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)
Jan 13, 2022 07:31AM BridgeBio (BBIO) Announces Pact with Amgen (AMGN) to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C M
Jan 13, 2022 07:30AM BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G1
Jan 13, 2022 07:30AM BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G1
Dec 27, 2021 07:00AM BridgeBio Pharma Inc. (BBIO) Reports Disappointing Month 12 Topline Results from Phase 3 ATTRibute-CM Study
Dec 27, 2021 07:00AM BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study
Dec 27, 2021 07:00AM BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study
Dec 10, 2021 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Dec 10, 2021 07:30AM BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Nov 19, 2021 07:31AM BridgeBio Pharma Inc. (BBIO) Collaborates with Helsinn Group to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
Nov 19, 2021 07:30AM BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
Nov 19, 2021 07:30AM BridgeBio Pharma and Helsinn Group Announce Strategic Collaboration to Co-Develop and Co-Commercialize BridgeBio’s Novel GPX4 Inhibitor in Multiple Cancer Tumor Types
Nov 18, 2021 07:32AM BridgeBio Pharma Inc. (BBIO) Enters Up to $750 Million in Non-Dilutive Debt Financing
Nov 18, 2021 07:30AM BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
Nov 18, 2021 07:30AM BridgeBio Pharma, Inc. Secures Up to $750 Million in Non-Dilutive Debt Financing
Nov 4, 2021 07:30AM BridgeBio Pharma Reports Third Quarter 2021 Financial Results and Business Update
View More Recent Stories View Older Stories